Human Heart, Spleen, and Perirenal Fat-Derived Mesenchymal Stem Cells Have Immunomodulatory Capacities

Abstract

Mesenchymal stem cells (MSCs) have important tissue repair functions and show potent immunosuppressive capacities in vitro. Although usually isolated from the bone marrow, MSCs have been identified in other tissues, including the skin and liver. In the present study, we isolated and characterized MSCs from human heart, spleen, and perirenal adipose tissue. MSCs from these different tissue sites were similar to those derived from bone marrow in that they expressed comparable levels of the cell-surface markers CD90, CD105, CD166, and HLA class I, were negative for CD34, CD45, HLA class II, CD80, and CD86 expression, and were capable of osteogenic and adipogenic differentiation. Like bone marrow-derived MSCs, MSCs from these different tissue sources inhibited the proliferation of alloactivated peripheral blood mononuclear cells (PBMCs), giving 85%, 79%, 79%, and 81% inhibition, respectively. Also in line with bone marrow-derived MSCs they inhibited proliferative responses of PBMCs to phytohemagglutinin, a nonspecific stimulator of lymphocyte proliferation, and reduced-memory T lymphocyte responses to tetanus toxoid. The results of this study demonstrate that MSCs from various tissues have similar immunophenotypes, in vitro immunosuppressive properties, and differentiation potential.

Generation and characterization of human cardiac resident and non-resident mesenchymal stem cell

“…Many subsequent studies have demonstrated that, umbilical cord and heart derived MSCs expressed identical levels of surface antigens such as CD90, CD44, CD105 and CD73. The present immunophenotyping pattern of MSCs derived from umbilical cord and human heart were found to be consistent with the reports of other groups (Hoogduijn et al 2007;Park et al 2007;Bai et al 2007). In addition, ) between experimental groups.…”

“…we have also demonstrated that MSCs derived from two different sources have the ability to undergo multilineage mesenchymal differentiation such as osteogenic and adipogenic differentiation (Can and Balci 2011;Hoogduijn et al 2007). Ion channels play a major role in cellular electrophysiological activities by regulating the potential of membranes.…”

“…Unfortunately, the quantity and qualities (proliferation efficiency and differentiation potential) of BM-MSCs are found to be significantly declined with aging that necessitated the search for an alternate source of MSCs (Rao and Mattson 2001;Mueller and Glowacki 2001). Almost all organs contain MSC as many studies reported the successful generation of MSCs from human skin, liver, heart, umbilical cord and cord blood (Hoogduijn et al 2007;Goodwin et al 2001;Feldmann et al 2005;Bieback et al 2004;Mc-Elreavey et al 1991;Wang 2004). Amongst, hUC-MSCs stand out a champion candidate due to unlimited availability of the samples, rapid in vitro expansion and lesser ethical issues (Wang et al 2004;Weiss et al 2006).…”

Wharton's Jelly Mesenchymal Stem Cells as Off-The-Shelf Cellular Therapeutics: A Closer Look into their Regenerative and Immunomodulatory Properties

“…The therapeutic benefits of BMMSCs is now established in several injury and disease models and preliminary data from clinical trials further confirm these claims [2]. In the recent past, several research groups have also identified mesenchymal stem-like populations from different post-natal and pre-natal tissues exhibiting tri-lineage differentiation potential (into osteogenic, adipogenic and chondrogenic lineages) [3,4]. These studies promise an easily accessible mesenchymal stem cell alternative to bone marrow.…”

Adipose derived stem cells for regenerative therapy in osteoarticular diseases

“…ASCs have been demonstrated to exhibit immunosuppressive effects both in vitro and in vivo and may contribute to a reduction in local inflammation through the secretion of soluble factors of the Interleukin 6 (IL-6) family [17][18][19][20]. IL-6 may have a random role in inflammation depending of the microenvironnement.…”